AusBiotech welcomes new Coalition ministry
17 September, 2013AusBiotech has welcomed the new Coalition ministry; in particular, the new Minister for Industry, Ian Macfarlane, who is returning to the portfolio he held from 2001 to 2007 when he was the Minister for Industry (Tourism and Resources).
Last call for nominations to the board of AusBiotech and 2013 Industry Excellence Awards
12 September, 2013Nominations will close shortly for candidates to nominate for the AusBiotech board of directors and for the Janssen 2013 Industry Excellence Awards, which recognise those who have made a significant contribution to the biotechnology industry.
SYNthesis med chem opens UK lab
10 September, 2013 by Dylan Bushell-EmblingAustralia-based CRO SYNthesis med chem has opened a UK facility to support its existing labs in Melbourne and Shanghai.
Australia’s first Tech Transfer Summit concludes with call for greater support for commercialisation
10 September, 2013TTS Australia 2013 brought together 150 leading tech transfer professionals from Australia and the international community to help build expertise and relationships that enable successful tech transfer - that which results in the translation of research into products to benefit our community.
Tailoring cancer drug dosage
10 September, 2013Scientists from Flinders University are collaborating with clinicians from Flinders Medical Centre to make a class of cancer drugs more effective by allowing patients to receive the dose that is best for them.
QRxPharma, FDA to discuss MoxDuo setback in October
09 September, 2013 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) will meet with the US FDA in October to discuss the issues raised in the latest Complete Response Letter for dual-opioid drug MoxDuo.
pSivida to present at two US investor conferences
09 September, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) will this week make presentations at the Rodman & Renshaw Annual Global Investment Conference and the Stifel Nicolaus Healthcare Conference.
iSonea wins CE Mark for AirSonea
09 September, 2013 by Dylan Bushell-EmblingiSonea (ASX:ISN) has gained the certification required for a CE Mark for its AirSonea wheeze monitoring tool, paving the way for an EU launch following its debuts in Australia and the US.
ACIP releases options paper on innovation patents
05 September, 2013The Advisory Council on Intellectual Property (ACIP) has just released an Options Paper for its Review of the Innovation Patent System. ACIP is seeking stakeholder comments on policy issues that address the full range of possibilities for the innovation patent system.
Alchemia narrows FY13 loss by $10.3m
03 September, 2013 by Dylan Bushell-EmblingRevenue from fonadaparinux sales and R&D Tax Incentive benefits helped Alchemia (ASX:ACL) reduce its FY13 loss by more than 68% to $4.8m.
AusBiotech responds to Qld review of its Gene Technology Act
03 September, 2013Amid 48 submissions, AusBiotech responded to the Queensland 'Review of the Gene Technology Act 2001 (Qld)', seeking support for a nationally consistent scheme for gene technology regulation.
Mesoblast bolsters cash position in FY13
30 August, 2013 by Dylan Bushell-EmblingMesoblast's (ASX:MSB) recent $170m capital raising allowed the company to close out FY13 with total available funds of $315m.
Call for nominations to the board of directors of AusBiotech
29 August, 2013Further to the notice of the forthcoming election for the board of directors of AusBiotech for 2013-14, nominations are now open for eligible AusBiotech members.
Coalition promises funding for agriculture R&D
29 August, 2013The Coalition has formally released its agricultural policy, which promises to allocate $100 million to research and development in the sector.
Pharmaxis reimbursement talks delayed in France
29 August, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) will cut back on resources dedicated to a launch of CF treatment Bronchitol in France, due to delays reaching agreement with the CEPS on reimbursement.
